Objective To develop and validate new regret scales and examine whether a decision aid affects different aspects of regret in the treatment choice for prostate cancer.
Introduction
For patients facing a choice between different treatment options, decision aids have been developed. However, these tools are still not widely implemented in daily oncology practice, possibly for fear of increasing anxiety 1 or uncertainty. 2 The fear of negative effects, for example reducing hope or increasing regret, makes some physicians hesitant to share all outcome information, 3 despite the fact that studies did not find negative effects. When patients with cancer were informed about a poor prognosis, hope was maintained. 4 And when they were involved in the treatment choice, regret was not increased. [5] [6] [7] This study focuses in more detail on different aspects of regret. To date, regret has been mainly studied using the Brehaut regret scale 8 (a questionnaire on decisional regret), or by separate questions such as 'Would you choose the same treatment again?'. 9 Such measures mainly focus on which treatment option was chosen. With respect to decision making, however, three types of regret have been distinguished: 10 (i) process regret, referring to the process leading up to the choice; (ii) option regret, referring to the treatment chosen; and (iii) outcome regret, referring to the results of the treatment. This study is the first to develop and validate separate regret subscales in order to measure different types of regret in the context of an actual treatment decision for cancer, that is prostate cancer.
Decision support and regret
Two opposing hypotheses can be formulated with regard to the relation between decision support and regret. The Decision Justification Theory 10, 11 posits that people tend to ask themselves whether a choice was justified. A 'careful and thorough (i.e. justified)' decision is expected to reduce feelings of regret. 10 This would suggest that a decision aid would decrease regret.
The medical psychological model, on the other hand, emphasizes the vulnerability of patients. Patients may prefer to avoid threatening or complicated information, [12] [13] [14] and they may prefer to avoid responsibility for the possible negative consequences of the choice. 15, 16 This would suggest that a decision aid would increase regret, particularly in patients experiencing a bad treatment outcome. In line with this reasoning, we examined patients with bad outcome as a separate group.
The study focused on two questions: (i) whether a decision aid affects regret, and (ii) what the effect is in patients with poor outcome in terms of serious side-effects.
Methods

Regret scales
To measure different aspects of regret, 18 regret statements were developed (Table 1) , in part derived from previous studies. 8, 9, 11, [17] [18] [19] Patients indicated to what extent they agreed with the statements, on a scale from 1 (completely disagree) to 5 (completely agree). Three aspects of regret 10 were distinguished: (i) process regret, about the process leading up to the choice, with items such as 'I made a well-informed choice', and (ii) option regret, about the treatment chosen, with items such as 'I would choose the same treatment again' and (iii) outcome regret, about the treatment results, with items such as 'I regret the way the treatment turned out for me'. Within each domain, items were averaged, recoding negatively worded items, to arrive at a regret score of 1 (no regret) to 5 (strong regret).
Trial design
The methods used in this trial have previously been described elsewhere. 20, 21 This was a prospective, parallel-group, multicentre randomized controlled trial between usual care and usual care plus decision aid ( Fig. 1 
Setting and patients
From 2008 to 2011, patients with primary localized prostate cancer (T1-3a), eligible for both radical prostatectomy and radiotherapy, were enrolled in three hospitals in the Netherlands, that is Radboud UMC Nijmegen, Canisius Wilhelmina Hospital in Nijmegen and Rijnstate Hospital in Arnhem. The latter are two large non-academic centres. Given the focus on the effect of serious side-effects, patients wanting active surveillance were not included in the study. Other exclusion criteria were mental/cognitive problems, and inadequate knowledge of the Dutch language, as assessed by the physician. The study was approved by the ethics committees of the participating hospitals.
Randomization
Enrolled patients were individually randomized to (i) the usual care group, which discussed the treatment choice with their specialist, or (ii) the decision aid group, which, in addition, had the decision aid presented by the researcher (JvTG). Randomization was imbalanced (1 : 2) to have a large enough decision aid group to answer separate research questions, reported elsewhere. 20 Randomization was centralized to avoid allocation bias and was blocked in groups of 3 per hospital, thus stratifying for hospital site.
Procedure
During the first consultation, the urologist mentioned that different treatment options were available. Patients who wanted active surveillance were not eligible for the study. The urologists mentioned the study to all remaining eligible patients. For these patients, urologists were instructed to describe the treatment options briefly and not to decide on a treatment within the first consultation. Written informed consent was obtained after the patients received additional information about the study from the researcher. Subsequently, patients were randomized to the usual care group or the decision aid group, as described above. The decision aid was presented to the decision aid group only, about a week after the drop out due to non-response (n = 5), deceased (n = 1) left for treatment elsewhere (n = 2) problems with questionnaires (n = 2)
drop out due to non-response (n = 2), deceased (n = 1) declined health (n = 1), stay abroad (n = 2) study closure (n = 2)
drop out due to non-response (n = 5) study closure (n = 1) consultation with the urologist, in a separate consultation with the researcher. A single researcher was used to obtain a standardized presentation of the decision aid, thus minimizing the effect of variation between caregivers. Finally, all patients had a second consultation with the urologist to discuss and decide on the treatment choice.
Decision aid
The decision aid was developed according to the IPDAS criteria. 22 It explained that there are different treatment options with different pros and cons. Radical prostatectomy (by open, laparoscopic or robot-assisted procedure) and external beam radiotherapy were presented to all patients. A third option, brachytherapy, was presented only to eligible patients.
During the decision aid consultation with the researcher, first the main features of each treatment were described in terms of procedures involved. Risk information regarding the outcome (bNED and survival) and side-effects (erectile, urinary and bowel) was based on a literature search 20 and was provided in frequencies and visual aid formats. Figure 2 shows the information presented to most patients, that is low-/intermediate-risk patients (PSA ≤ 20 and Gleason ≤ 7 and T1T2). For patients at higher risk (PSA > 20, Gleason > 7 and/or T3a), the 10-year risk of prostate cancer specific mortality was adapted to 10 and 18% after radical prostatectomy and external beam radiotherapy, respectively. The information was also given to the patients to take home.
To clarify values, patients were encouraged to consider and discuss which pros and cons were most important to them, both during the decision aid consultation and at home using the written take-home information. The decision aid has been described in more detail elsewhere. 20 
Outcome measures and follow-up
Questionnaires were sent at baseline (t1), that is before the treatment choice was made; about 2 weeks later at pre-treatment (t2), that is after the treatment was chosen, but before it was carried out; and at 6 months (t3) and 12 months (t4) after the surgery or the last radiotherapy session. The first questionnaire (t1) collected baseline demographic and medical patient characteristics. Decision-related outcome measures (including regret) were assessed at t2 and/or later (see below).
Patients' characteristics
Tumour characteristics were extracted from the patients' medical records. Demographic variables were collected by questionnaire at t1.
Regret
Process regret was assessed at t2, right after the decision-making process and before treatment. Option regret and outcome regret were assessed 6 and 12 months after treatment, at t3 and t4. These new regret scales range from 1 (no regret) to 5 (strong regret). In addition, the Brehaut regret scale 8 was assessed at t3 and t4, ranging from 0 to 100, with items partly similar to our option regret scale.
Patient participation
At t2, perceived participation was assessed by asking 'Who decided on the treatment choice?', 23 with answers ranging from 'only the physician' to 'only me'. To be able to correct for possible baseline differences, baseline participation preference was measured at t1: 'Who should, in your opinion, decide on the treatment choice?'
Measures for validation
For the purpose of validating the regret scales, anxiety and depression from the HADS 24 and Satisfaction-Uncertainty and Decision Control from the Decisional Evaluation Scales 18 were assessed at t2, t3 and t4. The prostate-specific HR-QOL was assessed at t1, t3 and t4 by means of the EPIC scale. 25 Scores ranged from 0 to 100, with higher scores reflecting better functioning.
Statistical analysis
The validity of the newly developed regret scales was examined by factor analysis on the items (oblique rotation) and by analysing the correlations with anxiety/depression, the Decision Evaluation Scales and health-related quality of life. In addition, Crohnbach's alphas were calculated. Furthermore, the regret scores at 6 and 12 months after treatment were compared to examine the reproducibility of the scales.
To examine differences between the decision aid group and the usual care group, t-tests were used for continuous variables and chisquare tests for ordinal or dichotomous variables. When data were missing, scale values were calculated only if at least half of the items were filled out, using the mean of the scored items. For analysis, the participation level was dichotomized as patient involved ('together with physician', 'mainly me' or 'only me') vs. physician decided ('mainly physician' or 'only physician'). The effect of the decision aid on regret was analysed by ANOVA. Our primary research question for the intervention was whether a decision aid had an impact on regret. The effect of the decision aid on Brehaut regret, process regret, option regret and outcome regret was analysed. Variables were considered as possible confounding factors if they were related to the regret score and differed at baseline (P < 0.15) between the decision aid group and the usual care group. None of the demographic, medical or decisionrelated variables, however, were significantly related to any of the regret scales. Therefore, subsequent analyses (ANOVA) were not corrected for confounders, and unadjusted means are presented.
Our second a priori research question was whether the effect was different in patients with a bad treatment outcome. Therefore, the above analyses were repeated on those patients that had serious morbidity at t4. Serious morbidity, that is poor functional outcome, was defined as a decrease of 15 points or more on the 100point urinary, bowel and/or sexual summary EPIC score 25 compared to the patient's baseline score. This criterion represents a minimal important difference (MID) of half a standard deviation. 26 As standard deviations for the scales ranged from 8 to 30, the upper limit of 30 was chosen, resulting in a MID of 15.
Results
Patients
The patients in this study were described in more detail elsewhere. 20, 21 In total, 307 patients were approached for the study, of whom 36 declined (12%), representing an informed consent rate of 88%. 21 The patients who declined had a similar mean age as those who gave informed consent (65 vs. 64 years). Of the remaining 271 patients, 31 were not eligible; 14 were excluded because of other health problems, including cardiac problems and other tumours; and 17 because they chose active surveillance after all. Thus, 240 patients were included. Patient characteristics in the decision aid group and the usual care group were comparable for education, age, baseline physical functioning and tumour characteristics. 20 Within the decision aid group, 91 patients (56%) were eligible for brachytherapy and 16 patients (10%) were high-risk patients. Overall, 169 (71%) were treated by RP, 28 (12%) by BT and 42 (18%) by EBRT. 20 The new regret scales Tables 2 and 3 show results on the newly developed regret scales. Process regret was assessed by seven items. We categorized the other eleven items a priori into two subscales, option regret (7 items) and outcome regret (4 items); the loadings of the items in a factor analysis confirmed this categorization both at 6 and 12 months after treatment ( Table 2) . Cronbach's alphas for the scales on process regret and outcome regret were 0.95 and 0.79, respectively. For the option regret scale, Cronbach's alpha was 0.94, compared to 0.83 for the validated Brehaut scale.
To quantify the reproducibility of the scales, the scores at 6 months and 12 months after treatment were compared. Correlations between the scores at 6 and 12 months were 0.65 (P < 0.001) for outcome regret and 0.66 (P < 0.001) for option regret, compared to 0.56 (P < 0.001) for the Brehaut scale. This time difference is quite large, resulting in an underestimate of the reproducibility.
For the purpose of validating the regret scales, correlations were examined of process regret (t2) and option and outcome regret (t4) with other measures at the corresponding point in time (t2 or t4) ( Table 3 ). Process regret, option regret and outcome regret correlated significantly with the Decision Evaluation Scales (Satisfaction/ Uncertainty, Informed choice, Decision control), anxiety and depression (Table 3 ). Outcome regret also correlated well with health-related quality of life (urinary, bowel and sexual scores). All correlations were in the expected direction; that is, more regret was associated with more anxiety/depression and with less decision satisfaction, less informed choice, less decision control and lower scores on health-related QOL.
Effect of the decision aid
At baseline (t1), the preferred participation level was high; 86 and 88% of the patients in the decision aid group and the usual care group, respectively, indicated at baseline that the patient should be involved in the treatment decision ('together with the physician', or 'mainly me' or 'only me'). At t2, 95% of the patients in the decision aid group indicated that they actually had been involved in the decision, compared to 83% in the usual care group (P = 0.002). As such, the decision aid had the expected effect on patient participation.
At the same time, the decision aid did not affect regret scores at t4, when analysed in all patients ( Table 4 ). In Table 5 , regret was examined separately in patients with or without toxicity. Regret was not affected in patients without serious side-effects. However, in patients with serious side-effects, if anything, a trend to less option regret and less Brehaut regret was found when a decision aid had been used (P = 0.075 and P = 0.061, respectively, and effect sizes of 0.35 and 0.38, respectively).
Discussion
The decision aid did not affect regret in general. However, in patients experiencing sideeffects the use of the decision aid tended to lower regret compared to usual care.
Development of the regret scales
As part of this study, we developed regret subscales. The Crohnbach's alphas and the reproducibility of the regret scores were good. For the purpose of validating these scales, their correlations with other measures were examined. All correlations were in the expected direction; that is, more regret was associated with more anxiety/depression and with less decisional conflict and lower QOL. These findings confirm the concurrent validity of our regret scales.
Previous research showed a shift in how patients evaluated the decision-making process, depending on the treatment outcome: the better the outcome of the treatment, the easier they perceived the decision-making process in retrospect. 27 Others suggested that patients experiencing problems after treatment may shift more responsibility about the treatment decision to others and may believe to have had little choice. 28 To avoid such bias by treatment experience, process regret was only measured right after the decision-making process (t2).
Relation between decision support and regret
Previous studies examining the effect of decision support reported less regret 5, 29, 30 or no effect, 6, 7 which is in line with our results. In our study, the lack of an effect on regret in general could not be attributed to the decision aid being ineffective, because several effects of the decision aid were found on the level of participation and on treatment choice, as reported elsewhere. 20 Thus, with regard to our first research question, we can conclude that the decision aid did not induce regret in general.
However, a different result was found for an important patient group, that is those with serious side-effects. For these patients, a trend to less regret was found when a decision aid had been used compared to usual care. This effect was not caused by a difference in outcome or treatment choice between the decision aid group and the usual care group. In itself, poor outcome (in terms of functional or biochemical outcome) can lead to more regret, as Having serious side-effects was defined as a decrease of at least 15 points from baseline in EPIC score for either urinary, bowel and/ or sexual functioning.
is illustrated in Table 5 and as has been shown by previous research. 31 The decision aid, however, did not influence functional outcome, as a similar proportion of patients were faced with serious side-effects in the decision aid group and the control group, that is 66.7 and 66.0%, respectively. Secondly, to control for the effect of the decision aid on treatment choice, we separately analysed the data of patients who had all received the same treatment (i.e. radical prostatectomy). Again, we found no effect of the decision aid in patients with good functional outcome, and again, the decision aid was associated with a trend to less option and Brehaut regret in patients with poor functional outcome, with identical effect sizes of 0.35 and 0.38, respectively. These effects support the Decision Justification Theory, 10, 11 in that decision support may help patients to reach a careful decision, thus reducing feelings of regret later on. One could hypothesize that regret is also influenced by risk classification, with higher risk patients possibly experiencing less regret when faced with side-effects. Analyses showed that in patients with side-effects, regret did not differ between risk groups. Option regret, for example, is 1.71, 1.66 and 1.58 for low, intermediate and high risk, respectively (P = 0.75). However, explorative analyses with risk group included in the model for option regret, showed a main effect of decision aid (P = 0.047) and an interaction between risk group and decision aid (P = 0.013). In the setting of side-effects, the decision aid had more of a lowering effect on regret in intermediate-or high-risk patients than in low-risk patients. Option regret with or without decision aid was 1.77 vs. 
Limitations and strengths
The study was carried out in the context of prostate cancer, limiting generalization to other cancer types. Another limitation is the followup duration of 1 year post-treatment, which may be too short to fully capture the development of regret. In addition, the effect of poor outcome could only be analysed in terms of functional outcome, that is side-effects. Poor biochemical outcome such as PSA relapse was too scarce within the first year to be analysed separately. Furthermore, there is debate about the presentation of probabilities. The pie chart format in itself has been reported to lead to more errors and longer reaction times compared to other formats. 32 However, adding numbers to the pie charts, as in our risk presentation, eliminated this negative effect. 33 As numbers were provided next to the pie charts, our format appears to be suitable. Another limitation is the exclusion of patients preferring active surveillance. The second research question in this study focused on the effect of serious side-effects. The treatment option of active surveillance does not lead to side-effects. Therefore, patients on active surveillance were not suited for the second research question and were not included in the study. Moreover, at the time of the development of the decision aid, outcome data were not available for active surveillance in the same detail as for other treatments, and therefore, this option was not included in the overview (Fig. 2) . Still, exclusion of patients on active surveillance is a limitation, as they constitute a relevant patient group which may also be at risk for regret.
The values clarification in decision aids can be implicit (e.g. stimulating the patient to think about which treatment aspects are most important to him) or explicit (rating or ranking different treatment aspects). Our approach involves an implicit values clarification rather than an explicit one. In recent years, there is debate on whether explicit values clarification exercises actually improve the quality of decision making. 34, 35 A strength of this study is that patient participation and other effects of the decision aid were assessed before the treatment was executed, avoiding bias by treatment experiences. In addition, this is a prospective study, eliminating recall bias. This study is the first to measure different types of regret in the context of an actual treatment decision. Most studies to date used the Brehaut scale, focusing on option regret. Our study provided new insights for two additional aspects of regret, namely process regret and outcome regret.
Conclusion
Within the context of treatment choice for prostate cancer, regret was not increased by a decision aid in this study, nor in previous studies. [5] [6] [7] 29 If anything, our data and reports by others 5, 29, 30 suggest that decision support may tend to lower regret, particularly for an important patient group, that is patients with serious morbidity. Exploratory analyses suggest that intermediate-and high-risk patients benefitted most from the decision aid. Although more research is needed, the newly developed regret scales may be of value in distinguishing between different aspects of regret, that is process, option and outcome regret.
